NRx PharmaceuticalsNASDAQ: NRXP

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q3 2024 Earnings Conference Call November 18, 2024 4:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Jonathan Javitt - Founder, Chairman and Chief Scientist Richard Narido - Interim Chief Financial Officer and Treasurer Michael Abrams - Incoming Chief Financial Officer Conference Call Participants Jason Kolbert - D. Boral Capital Ed Woo - Ascendiant Vernon Bernardino - H.C.

Industry veteran with extensive experience in key areas of focus Interim-CFO Richard Narido to focus on HOPE Therapeutics acquisition opportunities WILMINGTON, Del., Nov. 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it has appointed Michael Abrams as its permanent Chief Financial Officer.

WILMINGTON, Del. , Nov. 13, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will reschedule its third quarter and year to date 2024 results conference call to Monday November 18, 2024 at 4:30pm ET, to accommodate any additional corporate news.

The clinics are located in favorable locations, are revenue generating and EBITDA positive Clinics offer a comprehensive range of mental health services Acquisition is expected to be immediately accretive to revenue and EBITDA for HOPE and NRx MIAMI , Oct. 30, 2024 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq: NRXP), today announced signing a non-binding Letter of Intent (LOI) for acquisition of its first Interventional Psychiatry Clinics in Florida. These clinics are seen as top performers and will form the Company's foundation for growth in Florida.

MIAMI, FL., October 23, 2024 – PRISM MediaWire – NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, (“NRx,” the “Company”) and HOPE Therapeutics, Inc.

MIAMI, Oct. 23, 2024 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, (“NRx,” the “Company”) and HOPE Therapeutics, Inc., a medical and technology driven company and wholly-owned subsidiary of NRx, today announced they will be featured as a participating in the ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies.

Clinic to serve as the prototype for HOPE's network of Interventional Psychiatric Clinics Nationally recognized founder to become Chief Medical Innovation Officer of HOPE, in order to implement and evolve the Company's standard of care across the HOPE network Acquisition would be immediately accretive to revenue and EBITDA for HOPE and NRx MIAMI , Oct. 3, 2024 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), today announced signing a non-binding Letter of Intent (LOI) for acquisition of a premier West Coast Interventional Psychiatric Clinic. Importantly, as a component of the acquisition, the founder of the clinic, a pioneer and nationally recognized leader in the use of advanced treatments for treatment of CNS disorders, has agreed to join HOPE as Chief Medical Innovation Officer (CMIO).

"How NRx Could Upend the Fight Against Depression and Suicide" RADNOR, Pa. , Sept. 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today highlighted that the Company's pipeline products NRX-100 and NRX-101 were featured in an article published on Psychiatrist.com.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Dr. Jonathan Javitt - Founder, Chairman and Chief Scientist Stephen Willard - Chief Executive Officer Richard Narido - Chief Financial Officer and Treasurer Conference Call Participants Ed Woo - Ascendiant Operator Good afternoon, everyone. And welcome to the NRx Pharmaceuticals Incorporated Second Quarter of 2024 Results Conference Call.